Shares of Sandoz fell after the company issued a more cautious outlook on top-line growth for 2026. The drop reflected investor concern about the company's revenue prospects in the year ahead.
Sandoz pointed to challenging conditions in Germany as a key factor weighing on its sales outlook. The company's home market has faced pressures that complicate its growth expectations.
The company also cited supply constraints for its biosimilar drugs, which may limit its ability to meet demand. Biosimilars, lower-cost versions of biologic medicines, are a core part of Sandoz's business, so any constraints on production or supply are closely watched by investors.
The revised guidance signals a more measured view of growth for the year, and the market response reflected that shift in expectations.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing